Dr Reddys Laboratories (RDY) EPS (Basic) (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported EPS (Basic) for 15 consecutive years, with $0.21 the latest figure, recorded in Q2 2023.

• Quarterly EPS (Basic) changed N/A year-over-year to $0.21 in Q2 2023, while the trailing twelve-month figure through Mar 2026 was $0.21 (down 48.67% YoY) and the FY2026 annual result came in at $0.55, down 31.18% from the prior year.
• EPS (Basic) improved to $0.21 in Q2 2023 per RDY's latest filing, from $0.2 in the prior quarter.
• Over the last five years, EPS (Basic) for RDY reached as high as $0.21 in Q2 2023 and fell as low as -$0.13 in Q3 2020.
• A 5-year average of $0.1 and a median of $0.13 in 2022 frame the typical range for EPS (Basic).
• The largest YoY upside for EPS (Basic) was 49.14% in 2019 against a maximum downside of 192.96% in 2019.
• Year by year, EPS (Basic) stood at -$0.1 in 2019, then plunged by 35.13% to -$0.13 in 2020, then surged by 224.01% to $0.16 in 2021, then fell by 12.71% to $0.14 in 2022, then surged by 52.0% to $0.21 in 2023.
• According to Business Quant data, EPS (Basic) over the past three periods registered $0.21, $0.2, and $0.14 for Q2 2023, Q1 2023, and Q4 2022 respectively.